Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Scandinavian Journal of Urology and Nephrology
|
November 5, 2003
Prostate cancer--prevalence-based healthcare costs
Anders Norlund, Thor Alvegård, Thor Lithman, et al.
Cancer Causes & Control : CCC
|
July 19, 2014
Oral contraceptive use, parity, and constitutional characteristics in soft tissue sarcoma: a Swedish population-based case-control study 1988-2009
Philippe Wagner, Thor Alvegård, Jonas Ranstam, et al.
Clinical Therapeutics
|
October 9, 2008
Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis
Ola Ghatnekar, Thor Alvegård, Nils Conradi, et al.
Seminars in Oncology
|
August 12, 2009
Translocation-related sarcomas
Fredrik Mertens, Cristina R Antonescu, Peter Hohenberger, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 22, 2008
Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: a Scandinavian sarcoma group study
Nina L Jebsen, Clement S Trovik, Henrik C F Bauer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 2, 2016
Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?
Mikael Eriksson, Peter Reichardt, Kirsten Sundby Hall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
JAMA Oncology
|
May 30, 2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
JAMA
|
March 29, 2012
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Scandinavian Journal of Urology and Nephrology
|
November 5, 2003
Prostate cancer--prevalence-based healthcare costs
Anders Norlund, Thor Alvegård, Thor Lithman, et al.
Cancer Causes & Control : CCC
|
July 19, 2014
Oral contraceptive use, parity, and constitutional characteristics in soft tissue sarcoma: a Swedish population-based case-control study 1988-2009
Philippe Wagner, Thor Alvegård, Jonas Ranstam, et al.
Clinical Therapeutics
|
October 9, 2008
Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis
Ola Ghatnekar, Thor Alvegård, Nils Conradi, et al.
Seminars in Oncology
|
August 12, 2009
Translocation-related sarcomas
Fredrik Mertens, Cristina R Antonescu, Peter Hohenberger, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 22, 2008
Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: a Scandinavian sarcoma group study
Nina L Jebsen, Clement S Trovik, Henrik C F Bauer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 2, 2016
Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?
Mikael Eriksson, Peter Reichardt, Kirsten Sundby Hall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
JAMA Oncology
|
May 30, 2020
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
JAMA
|
March 29, 2012
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, et al.
Page
of 1